{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:31:45Z","timestamp":1762875105208},"reference-count":46,"publisher":"The Endocrine Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,8,1]]},"DOI":"10.1210\/jc.2007-0836","type":"journal-article","created":{"date-parts":[[2007,8,6]],"date-time":"2007-08-06T17:35:20Z","timestamp":1186421720000},"page":"2861-2865","source":"Crossref","is-referenced-by-count":76,"title":["Long-Term Management of Prolactinomas"],"prefix":"10.1210","volume":"92","author":[{"given":"Janet A.","family":"Schlechte","sequence":"first","affiliation":[{"name":"University of Iowa, Iowa City, Iowa 52242"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","reference":[{"key":"key\n\t\t\t\t2019041113595934600_R1","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1056\/NEJMcp025334","article-title":"Prolactinoma.","volume":"349","author":"Schlechte","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113595934600_R2","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1210\/jcem-60-4-698","article-title":"Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study.","volume":"60","author":"Molitch","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113595934600_R3","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJM199410063311403","article-title":"A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea.","volume":"331","author":"Webster","year":"1994","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113595934600_R4","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1210\/jcem.82.3.3822","article-title":"Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.","volume":"82","author":"Colao","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113595934600_R5","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/er.2005-9998","article-title":"Advances in the treatment of prolactinomas.","volume":"27","author":"Gillam","year":"2006","journal-title":"Endocr Rev"},{"key":"key\n\t\t\t\t2019041113595934600_R6","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1210\/jcem-68-2-412","article-title":"The natural history of untreated hyperprolactinemia: a prospective analysis.","volume":"68","author":"Schlechte","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113595934600_R7","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1227\/00006123-198302000-00008","article-title":"Natural history of microprolactinomas: six-year follow-up.","volume":"12","author":"Weiss","year":"1983","journal-title":"Neurosurgery"},{"key":"key\n\t\t\t\t2019041113595934600_R8","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0025-6196(12)62269-1","article-title":"Aging and the human pituitary gland","volume":"68","author":"Sano","year":"1993","journal-title":"Mayo Clin Proc"},{"key":"key\n\t\t\t\t2019041113595934600_R9","first-page":"2102","article-title":"Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study.","volume":"82","author":"Delgrange","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113595934600_R10","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1056\/NEJM198505233122106","article-title":"Pregnancy and the hyperprolactinemic woman.","volume":"312","author":"Molitch","year":"1985","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113595934600_R11","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1530\/acta.0.1110452","article-title":"Women with prolactinomas: effect of pregnancy and lactation on serum prolactin and on tumour growth.","volume":"111","author":"Holmgren","year":"1986","journal-title":"Acta Endocrinol (Copenh)"},{"key":"key\n\t\t\t\t2019041113595934600_R12","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/BF01727477","volume":"65","author":"Krupp","journal-title":"Klin Wochenschr"},{"key":"key\n\t\t\t\t2019041113595934600_R13","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0890-6238(96)00063-9","article-title":"Pregnancy outcome after treatment with the ergot derivative, cabergoline.","volume":"10","author":"Robert","year":"1996","journal-title":"Reprod Toxicol"},{"key":"key\n\t\t\t\t2019041113595934600_R14","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0015-0282(16)55819-1","article-title":"The safety of physiological estrogen plus progestin replacement therapy with oral contraceptive therapy in women with pathological hyperprolactinemia.","volume":"59","author":"Corenblum","year":"1993","journal-title":"Fertil Steril"},{"key":"key\n\t\t\t\t2019041113595934600_R15","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S0025-6196(12)64976-3","article-title":"Effects of estrogen on the human pituitary: a clinicopathologic study.","volume":"64","author":"Scheithauer","year":"1992","journal-title":"Mayo Clin Proc"},{"key":"key\n\t\t\t\t2019041113595934600_R16","first-page":"753","article-title":"Pituitary adenomas and oral contraceptives: a multicenter case-control study.","volume-title":"Fertil Steril","author":"Pituitary Adenoma Study Group","year":"1983"},{"key":"key\n\t\t\t\t2019041113595934600_R17","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3109\/09513599209015553","article-title":"The effect of combined estrogen\/progesterone treatment in women with hyperprolactinemic amenorrhea.","volume":"6","author":"Fathy","year":"1992","journal-title":"Gynecol Endocrinol"},{"key":"key\n\t\t\t\t2019041113595934600_R18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0010-7824(98)00069-9","article-title":"Two year treatment with oral contraceptives in hyperprolactinemic patients.","volume":"58","author":"Testra","year":"1998","journal-title":"Contraception"},{"key":"key\n\t\t\t\t2019041113595934600_R19","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1365-2265.1996.00824.x","article-title":"Long-term follow-up of patients with hyperprolactinaemia.","volume":"45","author":"Jeffcoate","year":"1996","journal-title":"Clin Endocrinol (Oxf)"},{"key":"key\n\t\t\t\t2019041113595934600_R20","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/oxfordjournals.humrep.a137010","article-title":"Is pregnancy the best treatment for hyperprolactinaemia?","volume":"4","author":"Crosignani","year":"1989","journal-title":"Hum Reprod"},{"key":"key\n\t\t\t\t2019041113595934600_R21","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0015-0282(16)55219-4","article-title":"Pregnancy-associated subacute hemorrhage into a prolactinoma resulting in diabetes insipidus.","volume":"58","author":"Freeman","year":"1992","journal-title":"Fertil Steril"},{"key":"key\n\t\t\t\t2019041113595934600_R22","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1046\/j.1365-2265.2001.01190.x","article-title":"The effect of menopause on prolactin levels in patients with hyperprolactinaemia.","volume":"54","author":"Karunakaran","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"key\n\t\t\t\t2019041113595934600_R23","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1210\/jcem-58-6-1179","article-title":"Perivascular fibrosis in prolactinomas: is it increased by bromocriptine?","volume":"58","author":"Landolt","year":"1984","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113595934600_R24","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0140-6736(84)90480-X","article-title":"Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas.","volume":"2","author":"Johnston","year":"1984","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041113595934600_R25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1530\/acta.0.1040139","article-title":"Follow-up of patients with prolactinomas after discontinuation of long-term therapy with bromocriptine.","volume":"104","author":"Zarate","year":"1983","journal-title":"Acta Endocrinol (Copenh)"},{"key":"key\n\t\t\t\t2019041113595934600_R26","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1210\/jcem-60-4-764","article-title":"Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal.","volume":"60","author":"Moriondo","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113595934600_R27","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2265.1987.tb01163.x","article-title":"Long-term treatment of hyperprolactinaemia with bromocriptine: effect of drug withdrawal.","volume":"27","author":"Wang","year":"1987","journal-title":"Clin Endocrinol (Oxf)"},{"key":"key\n\t\t\t\t2019041113595934600_R28","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0015-0282(16)59462-X","article-title":"Prolactin secretion and menstrual function after long-term bromocriptine treatment.","volume":"48","author":"Rasmussen","year":"1987","journal-title":"Fertil Steril"},{"key":"key\n\t\t\t\t2019041113595934600_R29","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1365-2265.1991.tb00289.x","article-title":"Withdrawal of bromocriptine after long-term therapy for macroadenomas; effect on plasma prolactin and tumour size.","volume":"34","author":"Van\u2019t Verlaat","year":"1991","journal-title":"Clin Endocrinol (Oxf)"},{"key":"key\n\t\t\t\t2019041113595934600_R30","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1530\/acta.0.1260489","article-title":"Cabergoline in long-term therapy of hyperprolactinemic disorders.","volume":"126","author":"Ferrari","year":"1992","journal-title":"Acta Endocrinol (Copenh)"},{"key":"key\n\t\t\t\t2019041113595934600_R31","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/BF03348016","article-title":"Use of cabergoline in the long-term treatment of hyperprolactinaemic and acromegalic patients.","volume":"20","author":"Muratori","year":"1997","journal-title":"J Endocrinol Invest"},{"key":"key\n\t\t\t\t2019041113595934600_R32","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/BF03343573","article-title":"Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenomas.","volume":"22","author":"Cannavo","year":"1999","journal-title":"J Endocrinol Invest"},{"key":"key\n\t\t\t\t2019041113595934600_R33","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1210\/jcem.87.8.8722","article-title":"Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal.","volume":"87","author":"Passos","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113595934600_R34","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa022657","article-title":"Withdrawal of long-term carbergoline therapy for tumoral and nontumoral hyperprolactinemia.","volume":"349","author":"Colao","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113595934600_R35","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1365-2265.2005.02293.x","article-title":"Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas.","volume":"63","author":"Biswas","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"key":"key\n\t\t\t\t2019041113595934600_R36","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000094312","article-title":"Long-term follow-up of prolactimomas: should dopamine agonist treatment be life-long?","volume":"35","author":"Guitelman","year":"2006","journal-title":"Front Horm Res"},{"key":"key\n\t\t\t\t2019041113595934600_R37","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1056\/NEJM198509123131103","article-title":"Low doses of dopamine agonists in the long-term treatment of macroprolactinomas.","volume":"313","author":"Liuzzi","year":"1985","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113595934600_R38","first-page":"651","article-title":"The surgical management of pituitary adenomas in a series of 2093 patients.","volume":"193","author":"Jane Jr","year":"2001","journal-title":"J Am Coll Surg"},{"key":"key\n\t\t\t\t2019041113595934600_R39","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1023\/A:1012905415868","article-title":"Current management of prolactinomas.","volume":"54","author":"Nomikos","year":"2001","journal-title":"J Neurooncol"},{"key":"key\n\t\t\t\t2019041113595934600_R40","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1042-3680(02)00090-6","article-title":"Role of surgery in the treatment of microprolactinomas.","volume":"14","author":"Couldwell","year":"2003","journal-title":"Neurosurg Clin North Am"},{"key":"key\n\t\t\t\t2019041113595934600_R41","first-page":"409","article-title":"Ten year follow-up of microprolactinoma treated by transsphenoidal surgery.","volume":"309","author":"Thompson","year":"1994","journal-title":"BMJ"},{"key":"key\n\t\t\t\t2019041113595934600_R42","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1001\/archneur.62.8.1290","article-title":"Pleuropulmonary fibrosis after long-term pergolide for Parkinson disease.","volume":"62","author":"Tintner","year":"2005","journal-title":"Arch Neurol"},{"key":"key\n\t\t\t\t2019041113595934600_R43","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1001\/archinte.1988.00380100089019","article-title":"Pleuropulmonary disease during bromocriptine treatment of Parkinson\u2019s disease.","volume":"148","author":"McElvaney","year":"1988","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t2019041113595934600_R44","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson\u2019s disease.","volume":"356","author":"Zanettini","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113595934600_R45","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","article-title":"Dopamine agonists and the risk of cardiac valve regurgitation.","volume":"356","author":"Schade","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113595934600_R46","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1210\/jc.2002-020426","article-title":"The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of giant prolactinoma.","volume":"87","author":"Gillam","year":"2002","journal-title":"J Clin Endocrinol Metab"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/92\/8\/2861\/10402252\/jcem2861.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T19:45:40Z","timestamp":1556739940000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/92\/8\/2861\/2597201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,1]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2007,8,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2007-0836","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,1]]}}}